Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease

• Published in: Journal of clinical pharmacy and therapeutics Vol. 23; no. 3; pp. 161 - 170
• Main Author: Tanaka, E.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01.06.1998; Blackwell
• Subjects: Biological and medical sciences; Biotransformation; Cytochrome P-450 Enzyme System - classification; Cytochrome P-450 Enzyme System - genetics; Cytochrome P-450 Enzyme System - metabolism; General pharmacology; Humans; Isoenzymes - metabolism; Liver Diseases - enzymology; Liver Diseases - metabolism; Liver Function Tests; Medical sciences; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Human; Drug; Pharmacogenetics; Isozyme; Cytochrome P450; Digestive diseases; Hepatic disease; Review; Metabolism; Pharmacokinetics
• ISSN: 0269-4727; 1365-2710
• DOI: 10.1046/j.1365-2710.1998.00135.x

Liver disease is associated with reduced metabolic capacity for drugs that are metabolized by oxidative biotransformation. Three cytochrome P450 (P450 or CYP) gene families in liver microsomes (CYP 1, CYP2 and CYP3) appear to be responsible for much of the drug metabolism that takes place. The genetic polymorphism of the CYPs responsible for debrisoquine/sparteine (CYP2D6) metabolism and S‐mephenytoin (CYP2C19) metabolism has been well documented, but information on the impairment of each isoform in liver disease is still limited. There are two types of hepatic P450 function tests. One type consists of non‐genetic P450 function tests (CYP1A2, 2A6, 2C9/10, 2E1 and 3A3/4), and probe drugs include caffeine, catalysed by CYP1A2, coumarin by CYP2A6, phenytoin by CYP2C6, chlorzoxazone by CYP2E1, and nifedipine, erythromycin and lidocaine by CYP3A3/4. The second type of genetic P450 function tests (CYP2C19 and CYP2D6) involves probe drugs such as S‐mephenytoin, catalysed by CYP2C19, and debrisoquine and sparteine, catalysed by CYP2D6. The metabolism of the probe drugs used in non‐genetic P450 function tests in patients with liver disease falls into two categories: reduced (CYP1A2, CYP2C, 2E1 and 3A) and unchanged (CYP2C). In genetic P450 function tests there seems to be a lesser degree of inhibition in poor metabolizers (PMs) than extensive metabolizers (EMs) among patients with liver disease. There have been very few reports on changes in metabolism of the probe drugs used in genetic P450 function tests in liver disease. In this paper the subject is reviewed